199 related articles for article (PubMed ID: 17598983)
21. Mechanisms of mutant p53 stabilization in cancer.
Frum RA; Grossman SR
Subcell Biochem; 2014; 85():187-97. PubMed ID: 25201195
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
23. Functional analysis of the acetylation of human p53 in DNA damage responses.
Chung SK; Zhu S; Xu Y; Fu X
Protein Cell; 2014 Jul; 5(7):544-51. PubMed ID: 24691905
[TBL] [Abstract][Full Text] [Related]
24. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.
Vogiatzi F; Brandt DT; Schneikert J; Fuchs J; Grikscheit K; Wanzel M; Pavlakis E; Charles JP; Timofeev O; Nist A; Mernberger M; Kantelhardt EJ; Siebolts U; Bartel F; Jacob R; Rath A; Moll R; Grosse R; Stiewe T
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8433-E8442. PubMed ID: 27956623
[TBL] [Abstract][Full Text] [Related]
25. p53 mutation heterogeneity in cancer.
Soussi T; Lozano G
Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
[TBL] [Abstract][Full Text] [Related]
26. Transcription activity is required for p53-dependent tumor suppression.
Gaidarenko O; Xu Y
Oncogene; 2009 Dec; 28(49):4397-401. PubMed ID: 19767771
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
28. p53 mutations in cancer.
Muller PA; Vousden KH
Nat Cell Biol; 2013 Jan; 15(1):2-8. PubMed ID: 23263379
[TBL] [Abstract][Full Text] [Related]
29. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
30. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
31. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
32. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
[No Abstract] [Full Text] [Related]
33. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
34. The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models.
Attardi LD
Mutat Res; 2005 Jan; 569(1-2):145-57. PubMed ID: 15603759
[TBL] [Abstract][Full Text] [Related]
35. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model.
Murphy KL; Dennis AP; Rosen JM
FASEB J; 2000 Nov; 14(14):2291-302. PubMed ID: 11053251
[TBL] [Abstract][Full Text] [Related]
36. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
[TBL] [Abstract][Full Text] [Related]
37. Illuminating p53 function in cancer with genetically engineered mouse models.
Garcia PB; Attardi LD
Semin Cell Dev Biol; 2014 Mar; 27():74-85. PubMed ID: 24394915
[TBL] [Abstract][Full Text] [Related]
38. p53: balancing tumour suppression and implications for the clinic.
Buganim Y; Rotter V
Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
[TBL] [Abstract][Full Text] [Related]
39. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
[TBL] [Abstract][Full Text] [Related]
40. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
